SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Quoin Pharmaceuticals Ltd.

(Name of Issuer)

American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share

(Title of Class of Securities)

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☑ Rule 13d-1(b)
- ☐ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons StemPoint Capital LP	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially	5	Sole Voting Power 0.00

Owned by Each Reporting Person With:	6	Shared Voting Power 506,983.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 506,983.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 506,983.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 9.9 %
12		Type of Reporting Person (See Instructions) IA, PN

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons StemPoint Capital Management GP LLC
2		Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 506,983.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 506,983.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 506,983.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 9.9 %

12	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person: StemPoint Capital Management GP LLC is a limited liability company.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Michelle Ross	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 506,983.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 506,983.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 506,983.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 9.9 %	
12	Type of Reporting Person (See Instructions) HC, IN	

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Quoin Pharmaceuticals Ltd.

(b) Address of issuer's principal executive offices:

42127 Pleasant Forest Court, Ashburn, VA 20148-7349

Item 2.

(a) Name of person filing:

This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person").

(b) Address or principal business office or, if none, residence:

The business addresses of each Reporting Person is: 520 Madison Avenue, 19th Floor New York, NY 10022

(c) Citizenship:

StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware. StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware. Michelle Ross is a citizen of the United States of America.

(d) Title of class of securities:

American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☑ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☑ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 506,983 shares of American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share ("ADS"), consisting of consisting of (i) 236,234 shares of ADS, (ii) 173,596 shares of ADS through the exercise of a pre-funded warrant (the "Pre-Funded Warrants"), and (iii) 97,153 shares of Common Stock underlying warrants (with the Pre-Funded Warrants, the "Warrants"). The Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation").

(b) Percent of class:

Each Reporting Person may be deemed to beneficially own 9.9% shares of ADS, which is calculated based on (i) 4,804,161 ADS outstanding as of September 16, 2026, as disclosed in the Issuer's prospectus filed with the Securities and Exchange Commission on September 25, 2026, plus (i) 173,596 shares of ADS which may be acquired upon the exercise of the pre-funded warrants, and (ii) 97,153 shares of ADS which may be acquired upon the exercise of underlying warrants which are subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act. The foregoing excludes 107,762 shares of ADS underlying the Pre-Funded Warrants, which is subject to the Beneficial Ownership Limitation. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of the Reporting Persons' cover pages have been rounded down to 9.9%. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

-0-

(ii) Shared power to vote or to direct the vote:

506,983. Comment: Shared voting power includes 270,749 Warrants beneficially owned by the Reporting Persons.

(iii) Sole power to dispose or to direct the disposition of:

-0-

(iv) Shared power to dispose or to direct the disposition of:

506,983. Comment: Shared dispositive power includes 270,749 Pre-Funded Warrants beneficially owned by the Reporting Persons.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

StemPoint Capital LP

Signature: /s/ Sean C. Tan
Name/Title: Sean C. Tan, Authorized Signatory
Date: 11/16/2026

StemPoint Capital Management GP LLC

Signature: /s/ Sean C. Tan
Name/Title: Sean C. Tan, Authorized Signatory
Date: 11/16/2026

Michelle Ross

Signature: /s/ Michelle Ross
Name/Title: Michelle Ross
Date: 11/16/2026

Exhibit Information

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

Exhibit 99.1

JOINT FILING AGREEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

November 16, 2026

STEMPOINT CAPITAL LP

BY: STEMPOINT CAPITAL MANAGEMENT GP LLC
ITS GENERAL PARTNER

BY: /S/ SEAN C. TAN
NAME: SEAN C. TAN
TITLE: AUTHORIZED SIGNATORY

STEMPOINT CAPITAL MANAGEMENT GP LLC

BY: /S/ SEAN C. TAN
NAME: SEAN C. TAN
TITLE: AUTHORIZED SIGNATORY

MICHELLE ROSS

/S/ MICHELLE ROSS